# Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia

> **NCT00399971** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shenzhen Zhongxing Yangfan Biotech Co. Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Anemia, Aplastic

## Interventions

- **PROCEDURE:** Ex Vivo Immunotherapy
- **DRUG:** Ex vivo immunotherapy

## Key facts

- **NCT ID:** NCT00399971
- **Lead sponsor:** Shenzhen Zhongxing Yangfan Biotech Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2002-11
- **Primary completion:** 2009-06
- **Final completion:** 2009-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2008-11-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00399971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00399971, "Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00399971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*